Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
A15-20
Last updated

Report documents

  1. Extract of dossier assessment

    Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF-Dokument, 275 kB, EN, PDF
    Download file : Extract of dossier assessment (PDF-Dokument, 275 kB, EN, PDF)

  2. Dossier assessment

    Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF-Dokument, 598 kB, DE, PDF
    Download file : Dossier assessment (PDF-Dokument, 598 kB, DE, PDF)

Press releases

Secukinumab in plaque psoriasis: manufacturer dossier provided no hint of an added benefit

Partly lack of suitable data, partly no relevant differences between the treatment groups
Press release

Project details

Project no.
A15-20
Commission
Commission awarded on 29.05.2015 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A17-08
    Last updated

    Status: Commission completed

  2. Addendum

    Secukinumab - Addendum to Commission A15-20

    Project no.
    A15-44
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A15-53
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-78
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-79
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-80
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-51
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-69
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-68
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page